10-Q: Tevogen Bio Reports Q2 Loss, Halts Trials Amid Funding Gap

Tevogen Bio Holdings Inc. reported continued net losses and negative cash flows for Q2 2025, pausing clinical trials until further funding is secured despite recent capital raises and commitments.

Summary

• Tevogen Bio Holdings Inc. (TVGN) reported a net loss of $5.5 million for the three months ended June 30, 2025, a reduction from $9.7 million in the same period of 2024.
• For the six months ended June 30, 2025, the company incurred a net loss of $15.9 million, a shift from a net income of $1.6 million in the prior year period (which included a non-cash gain).
• Cash balance stood at $685,229 as of June 30, 2025, down from $1.3 million at December 31, 2024.
• The accumulated deficit increased to $129.3 million as of June 30, 2025.
• Net cash used in operating activities increased to $6.5 million for the six months ended June 30, 2025, compared to $5.1 million in the prior year.
• The company explicitly stated it "does not plan to initiate a clinical trial until additional funding is received."
• Management believes current cash, recent proceeds ($2.53 million net from ATM offering, $1.0 million KRHP grant in August 2025), available Loan Agreement funds ($24.0 million remaining), and a committed $7.0 million KRHP grant will provide adequate cash for at least the next 12 months.
• The company entered into a Sales Agreement in July 2025 to sell up to $50.0 million of common stock through an at-the-market (ATM) offering, having already sold approximately 2.3 million shares for $2.53 million net proceeds between July 3 and August 13, 2025.
• An unsecured Loan Agreement with The Patel Family, LLP provides up to $36.0 million, with $4.4 million drawn as of June 30, 2025.
• The company is in default on $1,651,000 in notes payable to Polar Multi-Strategy Master Fund.
• Material weaknesses in internal control over financial reporting were identified, leading to a conclusion that disclosure controls and procedures were not effective.

Sentiment

Score: 3

Explanation: While the company has promising early clinical data and access to significant committed funding, its current low cash balance, increasing operational cash burn, and the explicit halt of clinical trials until 'additional' funding is secured indicate severe liquidity challenges. The default on existing debt and heavy reliance on related-party financing further underscore a high-risk financial position, casting significant doubt on its ability to progress its pipeline without substantial, potentially dilutive, capital infusions.

Positives

• Successfully completed a Phase 1 proof-of-concept trial for TVGN 489 (for COVID-19), observing no dose-limiting toxicities or significant treatment-related adverse events.
• TVGN 489 trial showed rapid reduction of viral load and did not prevent development of the patients' own T cell-related or antibody-related anti-COVID-19 immunity.
• None of the patients in the TVGN 489 trial reported progression of infection, reinfection, or development of Long COVID during the six-month follow-up period.
• Net loss for the three months ended June 30, 2025, decreased to $5.5 million from $9.7 million in the prior year period.
• Total operating expenses significantly decreased for both the three-month ($5.4 million vs $8.6 million) and six-month ($15.8 million vs $38.1 million) periods ended June 30, 2025, primarily due to lower non-cash stock-based compensation.
• Secured access to significant potential funding through a $50.0 million ATM equity offering and a $36.0 million unsecured line of credit, with $24.0 million remaining available.
• Received recent grants of $1.0 million from KRHP in August 2025 and has a committed additional $7.0 million grant from KRHP.
• Consolidated office and laboratory operations to a single location in Warren, New Jersey, which began operations in July 2025.

Negatives

• Continued to incur net losses and negative cash flows from operations since inception, with an accumulated deficit of $129.3 million as of June 30, 2025.
• Cash balance significantly decreased to $685,229 at June 30, 2025, from $1.3 million at December 31, 2024.
• Net cash used in operating activities increased to $6.5 million for the six months ended June 30, 2025, indicating a higher cash burn rate.
• The company explicitly stated it "does not plan to initiate a clinical trial until additional funding is received," indicating a delay in core development activities.
• In default on $1,651,000 in notes payable to Polar Multi-Strategy Master Fund.
• Identified material weaknesses in internal control over financial reporting, leading to a conclusion that disclosure controls and procedures were not effective.
• Significant reliance on related party funding (The Patel Family, LLP and KRHP LLC) for capital and operational support.
• Potential for substantial dilution to stockholders from future equity raises, including the ATM offering, conversion of preferred stock, and stock-based interest/principal payments on the Loan Agreement.

Risks

• Requires substantial additional financing to pursue business objectives and fund operations, which may not be available on acceptable terms or at all.
• Failure to obtain necessary capital could force delays, reductions, or termination of product development, commercialization efforts, or other operations, affecting future viability.
• Uncertainties inherent in the execution, cost, and completion of pre-clinical studies and clinical trials.
• Risks related to regulatory review and approval and commercial development of product candidates.
• Risks associated with intellectual property protection, including the ability to obtain, maintain, and enforce patents and operate without infringing on others' rights.
• Increasing use of AI could lead to liability, violation of data security and privacy laws, or reputational damage.
• Computer systems may fail or suffer security breaches.
• Limited operating history, making it difficult to evaluate future prospects.
• Terms of Preferred Stock, Loan Agreement, and Sales Agreement may negatively impact the ability to raise additional capital through equity or debt financings due to potential substantial dilution or restrictive covenants.
• The company is currently in default on certain notes payable, which could have adverse effects on its financial standing and ability to secure future funding.

Future Outlook

The company anticipates incurring additional losses until it can generate significant sales from product candidates. It does not plan to initiate a clinical trial until additional funding is received. Research and development expenses are expected to increase over the next several years due to increased manufacturing, shipping, storage of clinical batches, personnel costs, and planned clinical trials. General and administrative expenses are also expected to rise to support continued R&D, potential commercialization efforts, and increased costs of operating as a public company. The company will need additional funding to fully implement its business plans and is evaluating various strategies including private placements, licensing, partnerships, and public offerings.

Management Comments

• "Management believes that cash of $685,229 as of June 30, 2025, net proceeds through August 13, 2025 of $2,533,023 pursuant to the Sales Agreement, and a capital contribution of $1,000,000 from KRHP LLC, received in August 2025, combined with the amounts available under the Loan Agreement, and the remaining commitment for a $7,000,000 grant from KRHP, will allow the Company to have adequate cash and financial resources to operate for at least the next 12 months from the date of issuance of these unaudited consolidated financial statements."
• "The Company does not plan to initiate a clinical trial until additional funding is received."
• "We believe our allogeneic, precision T cell technology, ExacTcellTM, has the potential to mainstream cell therapy with a new class of off-the-shelf T cell therapies with diverse applications across virology, oncology, and other areas."
• "We are focused on harnessing the potential of AI to expedite drug development, optimize laboratory processes and clinical trials, unravel complex biological data, improve patient outcomes, and pass on related savings to patients."
• "Our continued investment in our pipeline highlights our belief in future commercial viability of these products."

Industry Context

Tevogen Bio operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on immunotherapy and T-cell therapies. Its emphasis on 'off-the-shelf' (allogeneic) T-cell therapies aims to overcome the logistical and cost challenges associated with patient-specific (autologous) cell therapies, a key trend in the industry. The company's Tevogen.AI initiative aligns with the broader industry trend of leveraging artificial intelligence to accelerate drug discovery, optimize clinical development, and improve efficiency. However, as a clinical-stage company without revenue, it faces significant challenges common to the sector, including the need for substantial, continuous funding, navigating complex regulatory pathways, and competing with established pharmaceutical companies and other innovative biotech firms.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Currently have no material legal proceedings pending.

Related Party Transactions

• Loan Agreement with The Patel Family, LLP, providing an unsecured line of credit facility of up to $36.0 million.
• Purchase of Series A Preferred Stock ($2.0 million) and Series C Preferred Stock ($6.0 million) by The Patel Family, LLP.
• Non-refundable prepaid proceeds of $3.0 million received from The Patel Family, LLP towards the anticipated issuance of Series A-1 Preferred Stock.
• Sponsor Advisory Service Fee of $2.0 million incurred to SSVK Associates, LLC (Sponsor), partially settled in cash, offset against amounts due, and 150,000 shares of common stock.
• SSVK Associates, LLC (Sponsor) owes the company $158,819 for working capital expenses.
• Issuance of 40,000 Performance-Based RSUs to the wife of the CEO and 20,000 Performance-Based RSUs to Mehtaphoric Consulting Inc (controlled by the CFO's daughter) for advisory and IT services.
• Consulting agreement with Dr. Manmohan Patel (The Patel Family LLP) for advisory services, for which he was granted 6,000,000 RSUs.
• Master Services and Facilities Agreement (MSFA) with CD8 Technology Services LLC, which is associated with Dr. Manmohan Patel, for access to specialized manufacturing facilities.
• Received grants of $2.0 million (January 2025) and $1.0 million (August 2025) from KRHP LLC, which is affiliated with The Patel Family, LLP, with an additional $7.0 million committed.
• Received a $500,000 capital contribution from Ryan Saadi, the company's Chief Executive Officer.

Stakeholder Impact

• Shareholders face significant potential dilution from ongoing and future equity raises (ATM offering, preferred stock conversions, stock-based interest/principal payments on debt, earnout shares) and continued operational losses.
• Employees may experience uncertainty regarding long-term job security and development progress due to the company's financial constraints and the halt of clinical trials.
• Future patients could face delays in accessing potential new therapies like TVGN 489 due to the company's inability to initiate further clinical trials without additional funding.
• Creditors, particularly Polar Multi-Strategy Master Fund, are impacted by the company's default on $1,651,000 in notes payable, indicating increased credit risk.
• Suppliers may face risks related to payment timeliness, although accounts payable decreased in the current period.

Next Steps

• Obtain additional funding to initiate future clinical trials for TVGN 489 and other product candidates.
• Continue to evaluate different strategies for obtaining funding, including private placements, licensing, marketing arrangements, partnerships, and public offerings.
• Increase manufacturing, shipping, and storage of clinical batches required for future clinical trials.
• Expand research and development capabilities and build manufacturing infrastructure.
• Develop commercialization organization, including reimbursement, marketing, managed market, and distribution functions.
• Prepare regulatory filings for product candidates as development progresses.
• Address and remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company's explicit statement that it will not initiate further clinical trials until additional funding is secured, despite having access to committed funds, signals a critical and immediate liquidity challenge that directly impacts its core business progression. This, combined with a low cash balance, increasing cash burn from operations, a growing accumulated deficit, and a default on existing debt, paints a picture of significant financial distress. While the Phase 1 results for TVGN 489 are positive, the inability to advance the pipeline due to funding constraints, coupled with the high potential for further shareholder dilution from ongoing capital raises and identified material weaknesses in internal controls, makes the stock a high-risk investment with substantial downside potential. A seasoned investor would likely view these factors as strong indicators to exit or avoid the position.

Keywords

Biotechnology, Immunotherapy, T-cell therapy, Clinical Trials, Drug Development, COVID-19, Oncology, Artificial Intelligence, SEC Filing, 10-Q, Financial Results, Capital Raise, Liquidity, TVGN